* Merger talks expected to be treated as reverse takeover
* Silence shares suspended from trading
LONDON, Sept 29 British gene-silencing company
Silence Therapeutics (SLN.L) said on Tuesday it was in merger
talks with an unnamed company and its shares had been suspended
It said the talks were expected to be treated as a reverse
takeover, a move commonly used to allow a private company to get
a stock market listing without having to perform an initial
public offering. Instead, a company uses the target's shares to
give it a market presence.
The announcement followed a report the company was in talks
for a reverse takeover deal involving a privately held U.S.
Gene silencing allows scientists to turn off the genes that
can cause diseases, allowing the targeting of conditions such as
heart disease and arthritis.
(Reporting by Ben Deighton; Editing by Dan Lalor)